Key Highlights
Medicine · Diabetes & Endocrinology
A correspondence published in The Lancet challenges the assertion that short-acting insulin analogues offer only “tenuous” benefits compared to regular human insulin, as previously argued in the context of the WHO Model Essential Medicines List (EML). The authors argue that while affordability is a critical consideration for the EML, policy decisions should not overlook evidence on safety, adherence, and the lived experience of people with diabetes. For a clinical leader and advocate for advancing diabetes standards of care in India, this debate underscores the importance of balancing cost with real-world patient outcomes in therapeutic guidelines.
Novelty: 75%
Rigor: 82%
Significance: 88%
Validity: 80%
Clarity: 90%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
